Richard Oakley, Alzheimer’s Society associate director for research and innovation, called results for early Alzheimer’s an exciting sign of a potential treatment targeting causes, not just symptoms. According to Euronews, a once-daily oral tablet reduced decline by 31% among 604 participants with early Alzheimer’s who were not taking other Alzheimer’s treatments.

According to Euronews, Experts not involved in the study called the findings encouraging or promising, while stressing that further research is needed. Oakley said AR1001 was developed specifically for Alzheimer’s and cautioned people against taking Viagra in an attempt to treat the disease.

According to The Guardian, AR1001 is a phosphodiesterase-5 inhibitor in the same drug family as Viagra, which is used to treat erectile dysfunction. University of Edinburgh professor Tara Spires-Jones said AR1001 might also directly stimulate brain-cell pathways that promote learning and memory.

According to The Guardian, Sheona Scales, research director at Alzheimer’s Research UK, said AR1001 takes a different approach from existing treatments and acts on an enzyme rather than targeting amyloid. Experts said the scientific community and drug regulators would need to scrutinize AR1001 before it could be prescribed for Alzheimer’s disease.

Alzheimer’s is the most common form of dementia, and the reports said there is currently no cure.